Abstract
Introduction
One of the fastest-growing segments of molecular diagnostics is nucleic acid
testing (NAT). NAT is central to the life sciences industry, to improved
healthcare, and to personalized medicine. Tools based on NAT are used to
discover new biomarkers and develop in vitro diagnostics. Companies large and
small are recognizing the value of NAT, and both R&D and dealmaking activity
is robust. Find out who the players are and how they are vying for commercial
success.
Get the Answers You Need to Shape Your Strategy
- NAT is a leading molecular diagnostics technology. What are the advantages
of NAT over other molecular diagnostics technologies? Which elements of NAT
will drive personalized medicine forward?
- Polymerase chain reaction (PCR) is one of the most common methods in the
NAT toolbox used to discover new biomarkers and develop diagnostics tests.
What other methods are commonly used for NAT? Which of these methods have the
most product development activity?
- Roche Diagnostics is the clear leader in molecular diagnostics. How do
Roche' s sales fi gures compare with those of smaller diagnostics players? What
does the competition look like within the smaller segments?
- How are companies using dealmaking to advance their positions?
- Infectious disease and oncology are the two main therapy areas for use of
NAT technologies. What are the growth trends and growth drivers within these
therapy areas? What companies are positioned to tap the opportunities?
Scope
- Importance of NAT for advancing personalized medicine: Use of and
rationale for NAT techniques and products to support the push for personalized
medicine.
- Key mergers and acquisitions (M&As), collaboration, and licensing
activities in NAT: Two tables featuring 92 alliances that occurred from
November 2007 through December 2008.
| 
View Cart
